SCM
Superstring Capital Management Portfolio holdings
AUM
$80.3M
This Quarter Return
-20.91%
1 Year Return
+68.23%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$79.3M
AUM Growth
+$79.3M
(-48%)
Cap. Flow
-$38.1M
Cap. Flow
% of AUM
-48.09%
Top 10 Holdings %
Top 10 Hldgs %
66.81%
Holding
58
New
21
Increased
4
Reduced
13
Closed
19
Top Buys
| 1 |
Legend Biotech
LEGN
|
$6.85M |
| 2 |
Terns Pharmaceuticals
TERN
|
$6.51M |
| 3 |
Zai Lab
ZLAB
|
$3.73M |
| 4 |
Arcellx
ACLX
|
$3.26M |
| 5 |
Arrowhead Research
ARWR
|
$2.89M |
Top Sells
| 1 |
IDEAYA Biosciences
IDYA
|
$9.53M |
| 2 |
Savara
SVRA
|
$7.52M |
| 3 |
Day One Biopharmaceuticals
DAWN
|
$5.78M |
| 4 |
Roivant Sciences
ROIV
|
$5.6M |
| 5 |
Ionis Pharmaceuticals
IONS
|
$5.24M |
Sector Composition
| 1 | Healthcare | 99.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cytokinetics
CYTK
$4.23B
| $10.2M | 12.82% |
187,633
-91,282
| -33% | -$4.95M |
|
|
2
Legend Biotech
LEGN
$6.41B
| $6.85M | 8.64% |
+154,665
| New | +$6.85M |
|
|
3
Terns Pharmaceuticals
TERN
$609M
| $6.51M | 8.21% |
+956,542
| New | +$6.51M |
|
4
BridgeBio Pharma
BBIO
$9.89B
| $5.57M | 7.02% |
219,837
-133,670
| -38% | -$3.39M |
|
5
89bio
ETNB
$1.34B
| $5.45M | 6.87% |
680,403
-260,884
| -28% | -$2.09M |
|
6
Nkarta
NKTX
$151M
| $5.18M | 6.53% |
875,999
-313,194
| -26% | -$1.85M |
|
|
7
Zai Lab
ZLAB
$3.68B
| $3.73M | 4.7% |
+215,178
| New | +$3.73M |
|
8
Keros Therapeutics
KROS
$618M
| $3.39M | 4.28% |
74,288
+40,460
| +120% | +$1.85M |
|
|
9
Arcellx
ACLX
$3.85B
| $3.26M | 4.11% |
+59,133
| New | +$3.26M |
|
|
10
Arrowhead Research
ARWR
$3.05B
| $2.89M | 3.64% |
+111,133
| New | +$2.89M |
|
11
Corbus Pharmaceuticals
CRBP
$115M
| $2.56M | 3.22% |
+56,468
| New | +$2.56M |
|
|
ONC
12
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $1.78M | 2.25% |
+12,508
| New | +$1.78M |
|
13
Fate Therapeutics
FATE
$120M
| $1.63M | 2.06% |
497,360
-423,116
| -46% | -$1.39M |
|
14
Allogene Therapeutics
ALLO
$251M
| $1.61M | 2.03% |
689,912
+168,663
| +32% | +$393K |
|
15
Pyxis Oncology
PYXS
$79.4M
| $1.6M | 2.02% |
484,443
-9,316
| -2% | -$30.8K |
|
16
Apogee Therapeutics
APGE
$2.17B
| $1.45M | 1.83% |
36,928
-7,940
| -18% | -$312K |
|
17
CytomX Therapeutics
CTMX
$336M
| $1.4M | 1.77% |
1,151,518
+472,115
| +69% | +$576K |
|
18
NewAmsterdam Pharma
NAMS
$2.71B
| $1.23M | 1.56% |
+64,213
| New | +$1.23M |
|
19
Tourmaline Bio
TRML
$601M
| $1.22M | 1.54% |
95,229
+25,257
| +36% | +$325K |
|
20
NovoCure
NVCR
$1.38B
| $1.15M | 1.44% |
+66,892
| New | +$1.15M |
|
21
Spyre Therapeutics
SYRE
$996M
| $1.07M | 1.35% |
+45,571
| New | +$1.07M |
|
22
Cabaletta Bio
CABA
$133M
| $1.05M | 1.32% |
139,895
-150,902
| -52% | -$1.13M |
|
23
Tango Therapeutics
TNGX
$747M
| $992K | 1.25% |
+115,571
| New | +$992K |
|
|
ALLK
24
DELISTED
Allakos
ALLK
| $941K | 1.19% |
940,578
-293,161
| -24% | -$293K |
|
25
Perspective Therapeutics
CATX
$250M
| $874K | 1.1% |
+87,638
| New | +$874K |
|